Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.38 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543788 | 1.00 | PLK1 (0.38) | PLK1PLK2BRD4BRDTPIK3R1 | |
| SCHEMBL2544712 | 0.90 | PLK1 (0.38) | PLK1PLK2BRD4BRDTPIK3R1 | |
| SCHEMBL523699 | 0.85 | PLK1 (0.41) | PLK1PLK2BRD4BRDT | |
| SCHEMBL6844602 | 0.84 | PRKDC (0.39) | PLK1PLK2BRD4BRDTPIK3R1 | |
| SCHEMBL4106903 | 0.84 | PLK1 (0.41) | PLK1BRD4BRDT | |
| SCHEMBL3702601 | 0.82 | PIK3R1 (0.34) | PLK1PLK2PIK3R1PIK3CA | |
| SCHEMBL2546566 | 0.81 | PIK3R1 (0.32) | PIK3R1PIK3CA | |
| SCHEMBL2546568 | 0.81 | PIK3R1 (0.32) | PIK3R1PIK3CA | |
| SCHEMBL25034678 | 0.78 | PLK1 (0.44) | PLK1PLK2BRD4BRDT | |
| SCHEMBL1675801 | 0.78 | PLK1 (0.44) | PLK1PLK2BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2190849-B1 | 4-(9-(3,3-DIFLUOROCYCLOPENTYL)-5,7,7-TRIMETHYL-6-OXO-6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-B[1,4]DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMA (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| EP-2190849-A2 | COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023269-A2 | 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, PRKCH, PACSIN2 | PLK1 28/4885PLK2 112/4885BRD4 868/4885 |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | MAP3K20, PRKCH, PACSIN2 | PLK1 28/4885PLK2 112/4885BRD4 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.